Drug intelligence / Profile preview

ITM-74

Development stage: Preclinical
Lead developer: ITG Isotope Garching
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ITM-74 is a diagnostic radiopharmaceutical candidate developed by Isotope Technologies Munich (ITM). It consists of a targeting ligand specific for Fibroblast Activation Protein (FAP) labeled with the positron-emitting radioisotope Gallium-68 (Ga-68). FAP is a cell-surface serine protease highly overexpressed on cancer-associated fibroblasts (CAFs) in the stroma of most epithelial tumors, as well as in non-malignant conditions involving active tissue remodeling, such as pulmonary fibrosis, rheumatoid arthritis, and cardiovascular inflammation. ITM-74 is designed for use with Positron Emission Tomography (PET) imaging to visualize FAP expression, serving as a diagnostic tool for patient stratification in theranostic applications (often paired with the therapeutic counterpart ITM-71) and for the assessment of disease activity in oncology, fibrosis, and inflammation.

Other names: Ga-68 ITM-74Ga68 ITM-74Ga 68 ITM-74[68Ga]Ga-ITM-74

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on ITM-74.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITM-74.

Explore the full profile